Financials EQUINOX NEPREMICNINE d.d.
Equities
EQNX
SI0031117813
Real Estate Development & Operations
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
54.5 EUR | 0.00% | +5.83% | +3.81% |
2022 | An unknown buyer acquired an unknown minority stake in EQUINOX NEPREMICNINE d.d. from Axor holding d.d. | CI |
2022 | EQUINOX NEPREMICNINE d.d. has completed an IPO. | CI |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 94.18 | 97.59 | - | - |
Enterprise Value (EV) 1 | 94.18 | 97.59 | 97.59 | 97.59 |
P/E ratio | 109 x | - | - | - |
Yield | - | 4.84% | 4.83% | 5.1% |
Capitalization / Revenue | - | 11.2 x | 10.9 x | 10.3 x |
EV / Revenue | - | 11.2 x | 10.9 x | 10.3 x |
EV / EBITDA | - | 14.4 x | 14 x | 13.3 x |
EV / FCF | - | 14.6 x | 24 x | 21.1 x |
FCF Yield | - | 6.86% | 4.17% | 4.74% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 1,794 | 1,791 | - | - |
Reference price 2 | 52.50 | 54.50 | 54.50 | 54.50 |
Announcement Date | 1/15/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | 8.706 | 8.986 | 9.466 |
EBITDA 1 | - | 6.773 | 6.959 | 7.345 |
EBIT 1 | - | 3.726 | 3.786 | 3.945 |
Operating Margin | - | 42.8% | 42.13% | 41.68% |
Earnings before Tax (EBT) | - | - | - | - |
Net income | 0.8691 | - | - | - |
Net margin | - | - | - | - |
EPS | 0.4800 | - | - | - |
Free Cash Flow 1 | - | 6.692 | 4.069 | 4.623 |
FCF margin | - | 76.87% | 45.28% | 48.84% |
FCF Conversion (EBITDA) | - | 98.8% | 58.47% | 62.94% |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share 2 | - | 2.640 | 2.630 | 2.780 |
Announcement Date | 1/15/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | 6.69 | 4.07 | 4.62 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex 1 | - | 0.5 | 2.3 | 2.3 |
Capex / Sales | - | 5.74% | 25.6% | 24.3% |
Announcement Date | 1/15/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.81% | 106M | |
+8.93% | 27.9B | |
-9.06% | 26.96B | |
+21.59% | 25.34B | |
+12.89% | 25.09B | |
+12.50% | 22.23B | |
+31.45% | 20.63B | |
-2.27% | 18.51B | |
+4.75% | 17.31B | |
+31.38% | 16.15B |
- Stock Market
- Equities
- EQNX Stock
- Financials EQUINOX NEPREMICNINE d.d.